Loading...
Current Alzheimer's disease clinical trials: Methods and placebo outcomes
BACKGROUND: Eighteen-month-long randomized, placebo-controlled clinical trials are common for phase II and phase III drug development for Alzheimer's disease (AD). Yet, no 18-month trial has shown statistically significant outcomes favoring the test drug. We examined characteristics and underly...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2009
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3321732/ https://ncbi.nlm.nih.gov/pubmed/19751918 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jalz.2009.07.038 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|